Which statin, what dose?

Drug and Therapeutics Bulletin

Volumn 45, Issue 5, 2007, Pages 33-37

[No Author Info available]

Author keywords

[No Author keywords available]

Indexed keywords

AMIODARONE; ANTIFUNGAL AGENT; ATORVASTATIN; C REACTIVE PROTEIN; CLARITHROMYCIN; CYCLOSPORIN; CYTOCHROME P450 3A4; DILTIAZEM; ERYTHROMYCIN; FLUINDOSTATIN; GEMFIBROZIL; GENERIC DRUG; GLIBENCLAMIDE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NICOTINIC ACID; PLACEBO; PRAVASTATIN; PROTEINASE INHIBITOR; ROSUVASTATIN; SIMVADOR; SIMVASTATIN; TELITHROMYCIN; UNCLASSIFIED DRUG; VERAPAMIL;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALCOHOL CONSUMPTION; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL; COST CONTROL; COST EFFECTIVENESS ANALYSIS; CREATINE KINASE BLOOD LEVEL; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CONTRAINDICATION; DRUG COST; DRUG DOSE COMPARISON; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG HALF LIFE; DRUG MEGADOSE; DRUG METABOLISM; DRUG SUBSTITUTION; DRUG WITHDRAWAL; ENZYME INHIBITION; HEART DEATH; HEART INFARCTION; HEART MUSCLE REVASCULARIZATION; HUMAN; HYPERCHOLESTEROLEMIA; HYPOGLYCEMIA; INDIVIDUALIZATION; LACTATION; LICENCE; LIVER DISEASE; LOW DRUG DOSE; MEDICAL DECISION MAKING; MUSCLE CRAMP; MUSCLE WEAKNESS; MYALGIA; PATIENT CARE; PATIENT COMPLIANCE; PATIENT SELECTION; PERIPHERAL NEUROPATHY; PRACTICE GUIDELINE; PREGNANCY; PRESCRIPTION; RHABDOMYOLYSIS; RISK REDUCTION; SIDE EFFECT; STROKE; TREATMENT OUTCOME; UNITED KINGDOM; VISUAL IMPAIRMENT;

DECISION MAKING; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERCHOLESTEROLEMIA; PRACTICE GUIDELINES AS TOPIC; TREATMENT OUTCOME;

EID: 36148982628     PISSN: 00126543     EISSN: None     Source Type: Journal    
DOI: 10.1136/dtb.2007.45533     Document Type: Article

References (25)

1. Schachter M. Chemical, pharmacokinetic and pharmacodynamic properties of statins: an update. Fundam Clin Pharmacol 2005; 19: 117-25.
2. Law MR et al. Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysis. BMJ 2003; 326: 1423: doi:10.1136/bmj.326.7404.1423.
3. Edwards JE, Moore RA. Statins in hypercholesterolaemia: A dose-specific meta-analysis of lipid changes in randomised, double blind trials. BMC Fam Pract 2003; 4: 18 [online]. Available: http://www.biomedcentral.com/content/pdf/1471-2296/4/18 [Accessed 19 April 2007].
4. Balk EM et al. Effects of statins on nonlipid serum markers associated with cardiovascular disease: a systematic review. Ann Intern Med 2003; 139: 670-82.
5. Cholesterol Treatment Trialists' (CTT) Collaborators. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90 056 participants in 14 randomised trials of statins. Lancet 2005; 366: 1267-48.
6. Zhou Z et al. Are statins created equal? Evidence from randomized trials of pravastatin, simvastatin, and atorvastatin for cardiovascular disease prevention. Am Heart J 2006; 151: 27341.
7. de Lemos JA et al. Early intensive vs a delayed conservative simvastatin strategy in patents with acute coronary syndromes. Phase Z of the A to Z trial. JAMA 2004; 292: 1307-16.
8. LaRosa JC et al. Intensive lipid lowering with atorvastatin in patents with stable coronary disease. N Engl J Med 2005; 352: 1425-35.
9. Pedersen TR et al. High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction. The IDEAL study: a randomized controlled trial. JAMA 2005; 294: 2437-45.
10. Cannon CP et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 2004; 350: 1495-504.
11. Moon JC et al. Statins audit: wrong question, wrong conclusions. Lancet 2007; 369: 640.
12. British Cardiac Society et al. JBS 2: Joint British Societies' guidelines on prevention of cardiovascular disease in clinical practice. Heart 2005; 91(suppl 5): v1-52.
13. Ong HT, Cheah JS. High-dose statins and the IDEAL study. JAMA 2006; 295: 2476-7.
14. McKenney JM. Pharmacological options for aggressive low-density lipoprotein cholesterol lowering: benefits versus risks. Am J Cardiol 2005; 96: 60E-66E.
15. Law M, Rudnicka AR. Statin safety: A systematic review. Am J Cardiol 2006; 97(suppl): 52C-60C.
16. Scottish Intercollegiate Guidelines Network, 2007. Risk estimation and the prevention of cardiovascular disease. A national clinical guideline. 97 [online]. Available: http:/www.sign.ac.uk/pdf/sign97.pdf [Accessed 19 April 2007).
17. 10 level in statin-related myopathy. Arch Neurol 2005; 62: 1709-12.
18. National Institute for Health and Clinical Excellence, 2006. Statins for the prevendon of cardiovascular events. Technology Appraisal 94. [online] Available: http://guidance.nice.org.uk/TA94/guidance/pdf/ English [Accessed 19 April 2007].
19. Moon JC, Bogle RG. Switching statins. BMJ 2006; 332: 1344-5.
20. Department of Health. National Service Framework for coronary heart disease [online]. Available: http://www.dh.gov.uk/assetRoot/04/05/75/ 26/04057526.pdf [Accessed 19 April 2007].
21. Boyle R. National policy on statin prescribing. Department of Health, November 2006.
22. Hayward RA et al. Narrative review: Lack of evidence for recommended low-density lipoprotein treatment targets: A solvable problem. Ann Intern Med 2006; 145: 520-30.
23. Minhas R. Eminence-based guidelines: a quality assessment of the second Joint British Societies' guidelines on the prevention of cardiovascular disease. Int J Clin Pract 2007; [epub ahead of print doi 10.1111/ j.1742-1241.2007.01310x].
24. Information Centre for Health and Social Care. Monitoring of national expenditure, 2007 [online]. Available: http://www.ic.nhs.uk/webfiles/ Services/PSU/This20year,%20top%2030%20BNF%20sections%20by20cost.xls [Accessed 19 April 2007].
25. Usher-Smith JA et al. Evaluation of the cost savings and clinical outcomes of switching patients from atorvastatin to simvastatin and losartan to candesartan in a Primary Care setting. Int J Clin Pract 2007; 61: 15-23.